Report Categories
View AllRecent Articles
View All
Peo Strengthens Market Sentiment Improves 20260403 1
State Street Materials Select Sector SPDR ETF XLB Investment Merit Analysis for Broad Materials Sector Exposure
Great GLDD Q4 earnings surge 545 percent past estimates shares flat despite beat
CLAR Clarus posts slight Q4 2025 EPS miss alongside 52 percent year over year revenue decline amid sector headwinds
CHSCO CHS B Pref latest quarterly earnings metrics remain unannounced with investors awaiting full operational performance details
US Charges Cubas Ral Castro with Murder in 1996 Plane Downing Case
IDEXX Laboratories IDXX Stock Consolidating at 54815 Next Move Ahead 20260520
Golden Sun Technology Group GSUN Faces Pressure as Shares Test Key Support
Sandisk Q1 2026 Earnings Strong EPS Beat Drives Stock Surge
GlobalFoundries GFS Establishes Dedicated Quantum Technology Solutions Unit
Toronto Blue Jays Legend Passes at Age Age Unknown from Source
Waymo Expands Temporary Pause of Robotaxi Services Across Five US Cities Following Flood Incidents
Jim Cramers Latest Claim on CrowdStrike Sparks Market Speculation
Arista Networks Faces PostEarnings SellOff Amid Heightened AI Market Expectations
General Motors Expands EV Lineup with New Cadillac Vistiq Featuring 300Mile Range
Genie Energy Ltd GNE Q1 2026 Earnings EPS Misses Estimates Stock Edges Higher
Southwest Gas Holdings SWX Q1 2026 Earnings Mixed Start as EPS Falls Short of Estimates
BNR Q3 2022 Earnings Narrower Loss Surprises Wall Street as Stock Drops 11 on Broader Biotech Selloff
GFS Q1 2026 Earnings Earnings Beat Expectations on EPS Shares Rise
LNKB Q4 2025 Earnings Earnings Miss Highlights Persistent Headwinds
US Energy Corp USEG Q1 2026 Earnings EPS Misses Estimates Despite Stock Rally
1RT Acquisition Corp ONCH Holds Steady Near Resistance RangeBound Action Continues
Newegg Commerce Nudges Higher as Consolidation Continues NEGG
Borealis Foods BRLS Edges Higher in Quiet Trading Resistance at 153 in Focus
Customers Bancorp Inc CUBI Edges Lower as Shares Test Key Support Levels
Allogene Therapeutics ALLO Surges 6 Can the Biotech Reclaim Key Resistance